Purification of Therapeutic Proteins

Downstream processing plays a vital role in the production of biotherapeutics as it aims to separate and purify the therapeutic protein from other contaminants and by-products in the fermentation or cell culture broth. Various chromatographic and filtration techniques are employed at this stage to capture the target protein based on differences in their physical and chemical properties such as size, charge, hydrophobicity etc.

Chromatography techniques like Affinity Chromatography utilizes the natural binding affinity of therapeutic proteins like antibodies to recover them from the crude harvest in a highly selective manner. The target protein is allowed to bind specifically to a ligand attached to the chromatography resin, while impurities pass through. Elution involves applying competitive ligands that disrupt this specific binding and recover the target protein. Other chromatography methods like Ion Exchange Chromatography separate proteins based on their surface charge. Hydrophobic Interaction Chromatography exploits differences in protein hydrophobicity. Size Exclusion Chromatography separates based on molecular size.

Membrane filtration techniques such as Tangential Flow Filtration are also widely used. They effectively remove cells, cell debris and aggregates through operations like clarification and concentration/diafiltration. Microfiltration with pore sizes of 0.1- 10 μm eliminates cells and cell debris. Ultrafiltration with pore sizes of 1-100 nm concentrates and purifies the target protein from other contaminating biomolecules based on molecular weight cut-off.

Viral Clearance and Viral Safety Testing

A key requirement during Downstream Processing is removal of potential viral contaminants to ensure viral safety of biopharmaceutical products. Since viruses are unavoidably present in living cell culture systems, multiple viral clearance validations are performed. Microfiltration and virus retentive nanofiltration can remove viruses physically based on size. Viral safety also relies on downstream unit operations like specific chromatography steps and low pH or solvent/detergent treatment that inactivate viruses.

Stringent process validating viral clearance studies are conducted using model viruses that represent worst-case enveloped and non-enveloped viruses. Manufacturing processes are validated to provide high logarithmic reduction values (LRVs) of viruses. Adventitious agent testing on raw materials, in-process and final drug substance helps identify and characterize any potential viral contaminants. Additional characterization includes tests for adventitious viruses during cell culture production and purification process. Cell banking and characterizaton also ensures starting materials are free of extraneous agents. Together these steps establish multiple barriers against viral contamination and ensure the safety of purified protein products.

Removal of Impurities and Process-Related Substances

Contaminants introduced during the upstream and downstream processing also need to be cleared. Leached protein A ligands, host cell proteins, DNA, endotoxins, process chemicals need to be reduced below permissible limits. Stringent in-process testing and online monitoring helps optimize clearance of these impurities which may elicit unwanted immune reactions.

Host cell proteins (HCP) are host cell components other than the product protein that are carried over during purification. Their removal is critical since residual HCP can cause immune reactions. HCP clearance involves multiple purification steps aided by affinity, IEX or HIC chromatography. DNA contamination from host cell breakdown products poses potential safety risks. Nuclease treatment aided by filtration helps remove DNA to very low ppb levels.

Endotoxins derived from bacterial cell wall components can trigger fever, hypotension if not removed below 0.5 EU/mg. Endotoxin removal relies on detergent facilitated hydrophobic interaction chromatography or polish with LAL reagent water. Process-related impurities from buffer components, leachable from resins are also limited by equipment qualification, RAW material testing and operation within validated conditions. Together these ensure a highly purified drug substance meeting all quality requirements.

Formulation and Fill-Finish of Drug Product

The final purified drug substance from the downstream process often requires appropriate formulation and fill-finish operations to produce the final drug product. Key considerations here include buffer exchange/diafiltration to transfer the protein into a suitable formulation buffer optimized for long-term stability. Concentration and dry weight determination helps establish protein recovery and concentration.

Sterile filtration through 0.2 or 0.1 μm filter capsules follows to remove any particulate matter. The filtrate is then filled aseptically either into vials or prefilled syringes/cartridges under ISO 5 environment. Other critical operations involve lyophilization to produce cakes or freezing in the final container. Quality control testing, labeling and packaging of the final drug product completes the overall manufacturing process. Critical process parameters during fill-finish are monitored to ensure sterility, safety, purity and potency of the final product.

Continuous Optimization of Downstream Processing

Downstream processing undergoes continuous improvements to enhance process economics, productivity and product quality. New techniques aid simpler, faster purification with less steps and higher protein yield. Chromatography resins are optimized for greater selectivity, capacity and throughput. Membranes with tighter pore sizes enable nanofiltration for virus removal. Continuous downstream processes are gaining popularity over batch operations for increased capacity.

Real-time monitoring tools and sensors facilitate tighter in-process control. Quality by Design (QbD) principles help establish robust processes less dependent on end-product testing. Data analytics and process analytical technologies (PAT) enable enhanced process understanding and greater control. Intensified continuous operations coupled with multi-modal chromatography are trends towards integrated purification platforms. Overall a combination of novel technologies and QbD principles ensures robust, optimized downstream processes meeting stringent regulatory expectations.

Get more insights on - Downstream Processing

For Deeper Insights, Find the Report in the Language that You want.

• French
• German
• Italian
• Russian
• Japanese
• Chinese
• Korean
• Portuguese

About Author:

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)